Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis Biotech Investing
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses over $100K to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU Biotech Investing
Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD Cannabis Investing News
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Last Week to Actively Participate in BELLUS Health Inc. Class Action and Lead Plaintiff Deadline: May 17, 2021 - Bronstein, Gewirtz & Grossman, LLC Biotech Investing
BELLUS Health to Present at the American Thoracic Society 2021 International Conference Biotech Investing
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS in The Lancet Biotech Investing
Portnoy Law Firm: Bellus Health Inc. Investors Last Days to Participate Actively in the Class Action Lawsuit Biotech Investing
